0.18USD
10.93 MUSD
50.70 MUSD
23.62 M
About Krystal Biotech, Inc.
Sector
Industry
CEO
Krish S. Krishnan
Website
Headquarters
Pittsburgh
Employees (FY)
229
Founded
2016
FIGI
BBG00HDGRHH7
Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of KRYS is 159.05 USD — it has decreased by 1.85% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Krystal Biotech, Inc. stocks are traded under the ticker KRYS.
Krystal Biotech, Inc. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
KRYS stock is 5.02% volatile and has beta coefficient of 0.92. Check out the list of the most volatile stocks — is Krystal Biotech, Inc. there?
KRYS earnings for the last quarter are 2.79 USD per share, whereas the estimation was −1.20 USD resulting in a 332.27% surprise. The estimated earnings for the next quarter are −0.31 USD per share. See more details about Krystal Biotech, Inc. earnings.
Krystal Biotech, Inc. revenue for the last quarter amounts to 8.56 M USD despite the estimated figure of 6.29 M USD. In the next quarter revenue is expected to reach 28.55 M USD.
Yes, you can track Krystal Biotech, Inc. financials in yearly and quarterly reports right on TradingView.
KRYS stock has fallen by 7.06% compared to the previous week, the month change is a 5.22% fall, over the last year Krystal Biotech, Inc. has showed a 87.12% increase.
KRYS net income for the last quarter is 8.69 M USD, while the quarter before that showed 80.75 M USD of net income which accounts for −89.24% change. Track more Krystal Biotech, Inc. financial stats to get the full picture.
Today Krystal Biotech, Inc. has the market capitalization of 4.50 B, it has decreased by 7.55% over the last week.
No, KRYS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, KRYS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Krystal Biotech, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 229.00 employees. See our rating of the largest employees — is Krystal Biotech, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Krystal Biotech, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Krystal Biotech, Inc. stock shows the buy signal. See more of Krystal Biotech, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Krystal Biotech, Inc. future price: according to them, KRYS price has a max estimate of 208.00 USD and a min estimate of 169.00 USD. Read a more detailed Krystal Biotech, Inc. forecast: see what analysts think of Krystal Biotech, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Krystal Biotech, Inc. EBITDA is −92.22 M USD, and current EBITDA margin is −181.90%. See more stats in Krystal Biotech, Inc. financial statements.